D. E. Shaw & Co., Inc. Alector, Inc. Transaction History

D. E. Shaw & Co., Inc.

$122 Billion
Q4 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Alector, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 368,977 shares of ALEC stock, worth $479,670. This represents 0.0% of its overall portfolio holdings.

Number of Shares

368,977

Previous 190,992 93.19%

Holding current value

$479,670

Previous $891,000 21.77%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$1.72 - $6.06 $306,134 - $1.08 Million	177,985 Added 93.19%	368,977 $697,000
Q3 2024 Nov 14, 2024	SELL	$4.34 - $6.58 $699,829 - $1.06 Million	-161,251 Reduced 45.78%	190,992 $891,000
Q2 2024 Aug 14, 2024	BUY	$4.19 - $6.23 $94,769 - $140,910	22,618 Added 6.86%	352,243 $1.6 Million
Q1 2024 May 15, 2024	BUY	$5.69 - $8.08 $827,769 - $1.18 Million	145,478 Added 79.0%	329,625 $1.98 Million
Q4 2023 Feb 14, 2024	BUY	$3.77 - $8.39 $245,536 - $546,432	65,129 Added 54.72%	184,147 $1.47 Million
Q3 2023 Nov 14, 2023	BUY	$5.2 - $8.77 $524,279 - $884,217	100,823 Added 554.12%	119,018 $771,000
Q2 2023 Aug 14, 2023	BUY	$5.86 - $7.93 $106,622 - $144,286	18,195 New	18,195 $109,000
Q4 2021 Feb 14, 2022	SELL	$19.35 - $25.54 $745,903 - $984,515	-38,548 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$21.65 - $39.49 $10,197 - $18,599	471 Added 1.24%	38,548 $880,000
Q2 2021 Aug 16, 2021	BUY	$15.5 - $22.48 $590,193 - $855,970	38,077 New	38,077 $793,000
Q1 2021 May 17, 2021	SELL	$14.84 - $22.23 $191,465 - $286,811	-12,902 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$9.4 - $16.7 $121,278 - $215,463	12,902 New	12,902 $195,000

About Alector, Inc.

Ticker ALEC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,563,904
Market Cap $107M
Description
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis dise...

More about ALEC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account